Our Focus

Commodities

©UNFPA. Midwives at the Provincial Health School Oudomxay, Laos, in 2013.

Commodities have the potential to be a game changer for the survival of pregnant women, new mothers and their babies, when implemented within a functioning health system.  Quality-assured MNH commodities are essential for reducing maternal and newborn mortality and achieving the Every Woman Every Newborn Everywhere targets.

However, commodities can only be effective if they are quality-assured and provided as part of a package of MNH interventions within a functioning health system, strengthening the capacity of health workers.
Building on the work of the UN Commission on Life-Saving Commodities, an Every Woman Every Newborn Everywhere working group is supporting countries in scaling up life-saving commodities to improve maternal and newborn health and wellbeing and reduce stillbirths.  The working group provides coordination and technical assistance to access the quality-assured commodities.

The impact

 ©UNFPA.
Gomezgani Mapala measures the pressure of  Jane, who delivered a baby recently, at Mzenga Health Centre, Nkhata Bay, Malawi in October 2021.

List of WHO-recommended quality-assured maternal health commodities, by indication and major condition

Commodity Presentation Indication
Elemental Iron & Folic Acid Tablets or capsules Anaemia prevention and treatment i
Oxytocin Ampoules PPH prevention and treatment
HS-Carbetocin Ampoules PPH prevention ii
Ergometrin Ampoules PPH prevention and treatment iii
Misoprostol Tablets PPH prevention and treatment / Abortion care iv
Tranexamic acid Ampoules PPH treatment
Uterine Balloon Tamponade (UBT) Devices PPH management
Non-pneumatic anti-shock garment (NASG) Devices PPH management
Calibrated drapes Devices PPH prevention and management

Footnotes:

i. If oxytocin not available or cold chain not assured.

ii. To be used as an alternative when oxytocin is unavailable.

iii. Ergometrin used when oxytocin is contraindicated.

iv. Misoprostol can be distributed antenatally in areas lacking skilled personnel.

Commodity Presentation Indication
Calcium Tablets PE prevention i
Aspirin Tablets PE prevention ii
Labetalol Tablets & ampoules Management of HT iii
Methyldopa Tablets Management of HT
Nifedipine Tablets Management of HT / Management of preterm labour iv
Hydralazine Ampoules Management of HT
Magnesium Sulphate Ampoules PE-E prevention and treatment / management of preterm labour for neuroprotection v

Footnotes:

i. For women with low dietary calcium intake.

ii. In women at moderate or high risk of preeclampsia.

iii. Suitable for emergency hypertension control.

iv. Used in case of preterm labor to manage hypertension.

v. For women at imminent risk of preterm birth before 32 weeks of gestation.

Commodity Presentation Indication
Oral Antibiotics Tablets Treatment of ASB / completion of initial parenteral treatment i
Parenteral Antibiotics Ampoules Prophylaxis at C-Section, perineal tears, instrumental delivery ii
Aqueous chlorhexidine or povidone iodine Solution Vaginal preparation for C-Section
Alcohol-based chlorhexidine Solution Skin preparation for C-Section

Footnotes:

i. According to local prevalence. Suggested antibiotics: Nitrofurantoin, ampicillin, first-generation cephalosporins.

ii. Use as per local antibiotic resistance patterns for surgical prophylaxis.

Commodity Presentation Indication
Tetanus toxoid vaccine Ampoules / vials Immunizations i
Inactivated influenza vaccine Ampoules / vials Immunizations ii
Rubella vaccine Ampoules / vials Immunizations iii
Dexamethasone or betamethasone Ampoules Antenatal corticosteroid therapy

Footnotes:

i. Recommended for neonatal tetanus prevention.

ii. Recommended in cases of maternal flu exposure to reduce neonatal mortality risks.

iii. Rubella vaccination to prevent congenital infections and neonatal complications.

Commodity Presentation Indication
Oral Antibiotic: Amoxicillin Dispersible tablets, Oral syrup Neonatal sepsis i
Parenteral Antibiotics: Ampicillin and Gentamicin, procaine penicillin Ampoule Neonatal sepsis ii

Footnotes:

i. Amoxicillin recommended based on local prevalence and resistance patterns.

ii. Combination therapy suggested to cover broad bacterial spectrum in sepsis cases.

Commodity Presentation Indication
Self-inflating bag with appropriate mask (size 0 and 1) Device Newborn Resuscitation i
Pulse oximeter Device Oxygen saturation monitoring ii
Oxygen source (cylinder or concentrator)
Oxygen source (cylinder or concentrator) Device Oxygen administration iii
Thermometer Device Routine care – thermal care
Digital weighing scale Device Routine care – Weight monitoring
Neonatal stethoscope Device Routine care
Respiration Counter Device Routine care – Respiratory rate measurement
Vitamin K Ampoule Routine care iv

Footnotes:

i. Essential for neonatal resuscitation in settings without advanced respiratory support.

ii. Necessary for monitoring oxygen saturation in premature and at-risk infants.

iii. Recommended in facilities without continuous oxygen supply for emergency cases.

iv. Vitamin K to prevent hemorrhagic disease in newborns.

Commodity Presentation Indication
Dual HIV/Syphilis RDTs Test kits HIV & syphilis screening i
Zidovudine and Niverapine Syrup HIV exposure prophylaxis ii
Nucleic Acid Test (NAT) for HIV Device Early infant diagnosis for HIV iii

Footnotes:

i. Recommended as part of routine antenatal care in high-risk regions.

ii. Prophylaxis for infants born to HIV-positive mothers to reduce transmission risk.

iii. Early testing to enable prompt initiation of antiretroviral therapy for exposed infants.

News and events

Resources

State of the world’s nursing report 2025

The 2025 edition of the State of the world’s nursing provides the most comprehensive and up-to-date analysis of the nursing workforce. The report features new indicators on critical areas for nursing, such as education capacity, advanced practice nursing and remuneration, policy priorities and a compilation of data from each WHO region.

Country profiles reflect each country’s national data and are available for download from the WHO National Health Workforce Accounts data portal.

Read more and download the report

Joint Every Woman Every Newborn Everywhere and Child Survival Action on the impact of ODA cuts

Every Woman Every Newborn Everywhere and Child Survival Action joint messages on the impact of ODA cuts on maternal, newborn and child health. Prepared for the 78th World Health Assembly, in May 2025.

The Midwifery Accelerator: Expanding health care for women and newborns

Investing in midwives is a cost-effective and sustainable strategy to improve maternal and newborn health and well-being and reduce mortality. There is ample evidence to show that care provided by midwives is women centric, significantly advances maternal and newborn health outcomes, strengthens health systems, and helps build future healthier generations.

The Midwifery Accelerator: Expanding Quality Care for Women and Newborns —developed in consultation with governments, global experts, UN agencies, civil society, and providers—calls on governments, funders and other stakeholders to invest in midwifery care to save and transform the lives of women and their newborns around the world.

Download the Midwifery Accelerator

See also:

Explore further and accelerate change